Amyotrophic lateral sclerosis: a clinical review

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily the motor system, but in which extra‐motor manifestations are increasingly recognized. The loss of upper and lower motor neurons in the motor cortex, the brain stem nuclei and the anterior horn of the spinal cord...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of neurology Jg. 27; H. 10; S. 1918 - 1929
Hauptverfasser:	Masrori, P., Van Damme, P.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England John Wiley & Sons, Inc 01.10.2020 John Wiley and Sons Inc
Schlagworte:	ALS and frontotemporal dementia Amyotrophic lateral sclerosis Autosomal dominant inheritance Brain stem Cortex (motor) Dementia Dementia disorders Differential diagnosis Epidemiology Frontotemporal dementia Genetics Health services Heredity Motor neurons Muscles Neurodegenerative diseases Pathogenesis Patients Review Spinal cord sporadic and familial ALS Symptom management TDP‐43 pathology TDP-43 pathology amyotrophic lateral sclerosis sporadic and familial ALS
ISSN:	1351-5101, 1468-1331, 1468-1331
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily the motor system, but in which extra‐motor manifestations are increasingly recognized. The loss of upper and lower motor neurons in the motor cortex, the brain stem nuclei and the anterior horn of the spinal cord gives rise to progressive muscle weakness and wasting. ALS often has a focal onset but subsequently spreads to different body regions, where failure of respiratory muscles typically limits survival to 2–5 years after disease onset. In up to 50% of cases, there are extra‐motor manifestations such as changes in behaviour, executive dysfunction and language problems. In 10%–15% of patients, these problems are severe enough to meet the clinical criteria of frontotemporal dementia (FTD). In 10% of ALS patients, the family history suggests an autosomal dominant inheritance pattern. The remaining 90% have no affected family members and are classified as sporadic ALS. The causes of ALS appear to be heterogeneous and are only partially understood. To date, more than 20 genes have been associated with ALS. The most common genetic cause is a hexanucleotide repeat expansion in the C9orf72 gene, responsible for 30%–50% of familial ALS and 7% of sporadic ALS. These expansions are also a frequent cause of frontotemporal dementia, emphasizing the molecular overlap between ALS and FTD. To this day there is no cure or effective treatment for ALS and the cornerstone of treatment remains multidisciplinary care, including nutritional and respiratory support and symptom management. In this review, different aspects of ALS are discussed, including epidemiology, aetiology, pathogenesis, clinical features, differential diagnosis, investigations, treatment and future prospects.
AbstractList	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily the motor system, but in which extra-motor manifestations are increasingly recognized. The loss of upper and lower motor neurons in the motor cortex, the brain stem nuclei and the anterior horn of the spinal cord gives rise to progressive muscle weakness and wasting. ALS often has a focal onset but subsequently spreads to different body regions, where failure of respiratory muscles typically limits survival to 2-5 years after disease onset. In up to 50% of cases, there are extra-motor manifestations such as changes in behaviour, executive dysfunction and language problems. In 10%-15% of patients, these problems are severe enough to meet the clinical criteria of frontotemporal dementia (FTD). In 10% of ALS patients, the family history suggests an autosomal dominant inheritance pattern. The remaining 90% have no affected family members and are classified as sporadic ALS. The causes of ALS appear to be heterogeneous and are only partially understood. To date, more than 20 genes have been associated with ALS. The most common genetic cause is a hexanucleotide repeat expansion in the C9orf72 gene, responsible for 30%-50% of familial ALS and 7% of sporadic ALS. These expansions are also a frequent cause of frontotemporal dementia, emphasizing the molecular overlap between ALS and FTD. To this day there is no cure or effective treatment for ALS and the cornerstone of treatment remains multidisciplinary care, including nutritional and respiratory support and symptom management. In this review, different aspects of ALS are discussed, including epidemiology, aetiology, pathogenesis, clinical features, differential diagnosis, investigations, treatment and future prospects. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily the motor system, but in which extra-motor manifestations are increasingly recognized. The loss of upper and lower motor neurons in the motor cortex, the brain stem nuclei and the anterior horn of the spinal cord gives rise to progressive muscle weakness and wasting. ALS often has a focal onset but subsequently spreads to different body regions, where failure of respiratory muscles typically limits survival to 2-5 years after disease onset. In up to 50% of cases, there are extra-motor manifestations such as changes in behaviour, executive dysfunction and language problems. In 10%-15% of patients, these problems are severe enough to meet the clinical criteria of frontotemporal dementia (FTD). In 10% of ALS patients, the family history suggests an autosomal dominant inheritance pattern. The remaining 90% have no affected family members and are classified as sporadic ALS. The causes of ALS appear to be heterogeneous and are only partially understood. To date, more than 20 genes have been associated with ALS. The most common genetic cause is a hexanucleotide repeat expansion in the C9orf72 gene, responsible for 30%-50% of familial ALS and 7% of sporadic ALS. These expansions are also a frequent cause of frontotemporal dementia, emphasizing the molecular overlap between ALS and FTD. To this day there is no cure or effective treatment for ALS and the cornerstone of treatment remains multidisciplinary care, including nutritional and respiratory support and symptom management. In this review, different aspects of ALS are discussed, including epidemiology, aetiology, pathogenesis, clinical features, differential diagnosis, investigations, treatment and future prospects.Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily the motor system, but in which extra-motor manifestations are increasingly recognized. The loss of upper and lower motor neurons in the motor cortex, the brain stem nuclei and the anterior horn of the spinal cord gives rise to progressive muscle weakness and wasting. ALS often has a focal onset but subsequently spreads to different body regions, where failure of respiratory muscles typically limits survival to 2-5 years after disease onset. In up to 50% of cases, there are extra-motor manifestations such as changes in behaviour, executive dysfunction and language problems. In 10%-15% of patients, these problems are severe enough to meet the clinical criteria of frontotemporal dementia (FTD). In 10% of ALS patients, the family history suggests an autosomal dominant inheritance pattern. The remaining 90% have no affected family members and are classified as sporadic ALS. The causes of ALS appear to be heterogeneous and are only partially understood. To date, more than 20 genes have been associated with ALS. The most common genetic cause is a hexanucleotide repeat expansion in the C9orf72 gene, responsible for 30%-50% of familial ALS and 7% of sporadic ALS. These expansions are also a frequent cause of frontotemporal dementia, emphasizing the molecular overlap between ALS and FTD. To this day there is no cure or effective treatment for ALS and the cornerstone of treatment remains multidisciplinary care, including nutritional and respiratory support and symptom management. In this review, different aspects of ALS are discussed, including epidemiology, aetiology, pathogenesis, clinical features, differential diagnosis, investigations, treatment and future prospects. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily the motor system, but in which extra‐motor manifestations are increasingly recognized. The loss of upper and lower motor neurons in the motor cortex, the brain stem nuclei and the anterior horn of the spinal cord gives rise to progressive muscle weakness and wasting. ALS often has a focal onset but subsequently spreads to different body regions, where failure of respiratory muscles typically limits survival to 2–5 years after disease onset. In up to 50% of cases, there are extra‐motor manifestations such as changes in behaviour, executive dysfunction and language problems. In 10%–15% of patients, these problems are severe enough to meet the clinical criteria of frontotemporal dementia (FTD). In 10% of ALS patients, the family history suggests an autosomal dominant inheritance pattern. The remaining 90% have no affected family members and are classified as sporadic ALS. The causes of ALS appear to be heterogeneous and are only partially understood. To date, more than 20 genes have been associated with ALS. The most common genetic cause is a hexanucleotide repeat expansion in the C9orf72 gene, responsible for 30%–50% of familial ALS and 7% of sporadic ALS. These expansions are also a frequent cause of frontotemporal dementia, emphasizing the molecular overlap between ALS and FTD. To this day there is no cure or effective treatment for ALS and the cornerstone of treatment remains multidisciplinary care, including nutritional and respiratory support and symptom management. In this review, different aspects of ALS are discussed, including epidemiology, aetiology, pathogenesis, clinical features, differential diagnosis, investigations, treatment and future prospects. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily the motor system, but in which extra‐motor manifestations are increasingly recognized. The loss of upper and lower motor neurons in the motor cortex, the brain stem nuclei and the anterior horn of the spinal cord gives rise to progressive muscle weakness and wasting. ALS often has a focal onset but subsequently spreads to different body regions, where failure of respiratory muscles typically limits survival to 2–5 years after disease onset. In up to 50% of cases, there are extra‐motor manifestations such as changes in behaviour, executive dysfunction and language problems. In 10%–15% of patients, these problems are severe enough to meet the clinical criteria of frontotemporal dementia (FTD). In 10% of ALS patients, the family history suggests an autosomal dominant inheritance pattern. The remaining 90% have no affected family members and are classified as sporadic ALS. The causes of ALS appear to be heterogeneous and are only partially understood. To date, more than 20 genes have been associated with ALS. The most common genetic cause is a hexanucleotide repeat expansion in the C9orf72 gene, responsible for 30%–50% of familial ALS and 7% of sporadic ALS. These expansions are also a frequent cause of frontotemporal dementia, emphasizing the molecular overlap between ALS and FTD. To this day there is no cure or effective treatment for ALS and the cornerstone of treatment remains multidisciplinary care, including nutritional and respiratory support and symptom management. In this review, different aspects of ALS are discussed, including epidemiology, aetiology, pathogenesis, clinical features, differential diagnosis, investigations, treatment and future prospects.
Author	Masrori, P. Van Damme, P.
AuthorAffiliation	2 Laboratory of Neurobiology Center for Brain and Disease Research VIB Leuven Belgium 1 Department of Neurosciences Experimental Neurology KU Leuven – University of Leuven Leuven Belgium 3 Department of Neurology University Hospitals Leuven Leuven Belgium
AuthorAffiliation_xml	– name: 1 Department of Neurosciences Experimental Neurology KU Leuven – University of Leuven Leuven Belgium – name: 2 Laboratory of Neurobiology Center for Brain and Disease Research VIB Leuven Belgium – name: 3 Department of Neurology University Hospitals Leuven Leuven Belgium
Author_xml	– sequence: 1 givenname: P. orcidid: 0000-0001-8247-1866 surname: Masrori fullname: Masrori, P. organization: University Hospitals Leuven – sequence: 2 givenname: P. orcidid: 0000-0002-4010-2357 surname: Van Damme fullname: Van Damme, P. email: philip.vandamme@uzleuven.be organization: University Hospitals Leuven
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/32526057$$D View this record in MEDLINE/PubMed
BookMark	eNp9kU9LAzEQxYMo1qoHv4AUvOhh20yy2e16EEqpf0D0oueQprM2Jd3UZFfptzfaWrSguSRMfvN4M69NditXISEnQLsQTw8r7ELKC75DDiDN-glwDrvxzQUkAii0SDuEGaWU5YzukxZngmVU5AeEDuZLV3u3mBrdsapGr2wnaIveBRMuO6qjramMjlWPbwbfj8heqWzA4_V9SJ6vR0_D2-T-8eZuOLhPtKAFT1CXBWpG-xMUY4Wq4FoBjyUcI9OKKtbPmdYcxCQrM2Acs3xMKXDNUhQM-SG5WukumvEcJxqrOlqTC2_myi-lU0b-_qnMVL64N5mLlHKeRoHztYB3rw2GWs5N0GitqtA1QbIUWNEvICsieraFzlzjqzhepFKW0xzyLFKnPx1trHwvMwIXK0DH5QWP5QYBKj-DkjEo-RVUZHtbrDa1qo37HMbY_zrejcXl39Jy9DBadXwAc3ajww
CitedBy_id	crossref_primary_10_1080_21678421_2025_2538599 crossref_primary_10_1016_j_jns_2024_123038 crossref_primary_10_1038_s41597_024_03597_2 crossref_primary_10_59556_japi_73_0931 crossref_primary_10_3389_fcell_2025_1550859 crossref_primary_10_3390_antiox14091078 crossref_primary_10_3390_ijms26072867 crossref_primary_10_1016_j_neurobiolaging_2023_03_004 crossref_primary_10_1007_s11940_025_00835_9 crossref_primary_10_1007_s00415_023_12037_x crossref_primary_10_1016_j_compbiolchem_2024_108211 crossref_primary_10_3390_ijms231911391 crossref_primary_10_3390_ijms24010087 crossref_primary_10_3892_mmr_2022_12662 crossref_primary_10_1055_a_2463_3385 crossref_primary_10_1007_s11325_023_02853_w crossref_primary_10_5014_ajot_2024_78S106 crossref_primary_10_1186_s12929_021_00766_y crossref_primary_10_1080_21678421_2025_2463943 crossref_primary_10_1186_s13244_022_01358_6 crossref_primary_10_3390_cells11132049 crossref_primary_10_3892_br_2024_1829 crossref_primary_10_1016_j_xhgg_2024_100318 crossref_primary_10_3390_cimb46060325 crossref_primary_10_1097_WCO_0000000000000984 crossref_primary_10_3390_ijms23115954 crossref_primary_10_1186_s13024_025_00851_y crossref_primary_10_3390_diagnostics13061016 crossref_primary_10_3389_fnmol_2024_1408159 crossref_primary_10_1080_21678421_2024_2320881 crossref_primary_10_3390_biomedicines9081000 crossref_primary_10_1007_s10072_024_07542_4 crossref_primary_10_1038_s12276_023_01144_4 crossref_primary_10_3390_antiox11010008 crossref_primary_10_1007_s00415_024_12219_1 crossref_primary_10_1136_pn_2022_003574 crossref_primary_10_1016_j_ymthe_2025_05_010 crossref_primary_10_1145_3757930 crossref_primary_10_1016_j_jddst_2021_102883 crossref_primary_10_3390_ijms23169364 crossref_primary_10_1038_s41573_022_00612_2 crossref_primary_10_1016_j_ymthe_2024_11_029 crossref_primary_10_1007_s11011_023_01296_2 crossref_primary_10_1007_s00401_024_02794_y crossref_primary_10_1016_j_ibneur_2023_01_006 crossref_primary_10_3390_pharmaceutics17040410 crossref_primary_10_1016_j_bbrc_2022_03_126 crossref_primary_10_1016_j_jns_2021_120021 crossref_primary_10_1007_s12035_025_04825_5 crossref_primary_10_1002_wrna_70026 crossref_primary_10_1002_acn3_51648 crossref_primary_10_1007_s00401_023_02569_x crossref_primary_10_1186_s40478_021_01228_0 crossref_primary_10_1186_s40478_024_01916_7 crossref_primary_10_1016_j_jns_2024_123177 crossref_primary_10_1016_j_nbd_2025_107036 crossref_primary_10_1016_j_neuroscience_2024_11_053 crossref_primary_10_15252_embj_2020106177 crossref_primary_10_3389_fnins_2024_1434404 crossref_primary_10_1016_j_arr_2024_102279 crossref_primary_10_1093_hmg_ddad163 crossref_primary_10_1042_EBC20210021 crossref_primary_10_3390_cells10061449 crossref_primary_10_3390_cells9102320 crossref_primary_10_3389_fnagi_2021_664965 crossref_primary_10_4103_1673_5374_358615 crossref_primary_10_1002_ptr_8192 crossref_primary_10_3390_brainsci15070696 crossref_primary_10_3390_molecules28052014 crossref_primary_10_1016_j_ijpharm_2025_125875 crossref_primary_10_1177_02611929211030417 crossref_primary_10_1080_21678421_2022_2150555 crossref_primary_10_1515_revneuro_2023_0155 crossref_primary_10_1016_j_rmed_2020_106277 crossref_primary_10_1016_j_ejrad_2024_111481 crossref_primary_10_1016_j_ymthe_2023_09_018 crossref_primary_10_1093_g3journal_jkab141 crossref_primary_10_1148_rg_240067 crossref_primary_10_1177_23333936251348143 crossref_primary_10_1002_acn3_70067 crossref_primary_10_1016_j_scr_2022_102870 crossref_primary_10_3390_life14080941 crossref_primary_10_1080_21678421_2024_2351177 crossref_primary_10_3390_cells14171336 crossref_primary_10_3390_cells13110888 crossref_primary_10_1016_j_brainresbull_2025_111349 crossref_primary_10_2147_IJN_S479819 crossref_primary_10_1002_acn3_51663 crossref_primary_10_3390_antiox14040401 crossref_primary_10_34133_bmr_0162 crossref_primary_10_1016_j_ebiom_2025_105907 crossref_primary_10_1038_s41582_023_00915_x crossref_primary_10_3389_fneur_2022_986882 crossref_primary_10_3390_cells12081180 crossref_primary_10_3390_ijms25094809 crossref_primary_10_3390_brainsci15020134 crossref_primary_10_1002_cmdc_202500447 crossref_primary_10_1080_21678421_2024_2334836 crossref_primary_10_3390_cells12081188 crossref_primary_10_1016_j_jns_2025_123508 crossref_primary_10_1186_s13024_022_00525_z crossref_primary_10_3389_fnmol_2021_681868 crossref_primary_10_1007_s12035_022_03063_3 crossref_primary_10_1007_s00429_023_02728_6 crossref_primary_10_3390_cells12071031 crossref_primary_10_3389_fncel_2022_1069617 crossref_primary_10_2147_CIA_S394286 crossref_primary_10_3390_life13040942 crossref_primary_10_1111_jnc_15906 crossref_primary_10_1016_j_hermed_2023_100771 crossref_primary_10_3390_pharmaceutics14122803 crossref_primary_10_1016_j_arr_2022_101756 crossref_primary_10_1007_s00018_021_03905_8 crossref_primary_10_1016_j_jpainsymman_2023_06_029 crossref_primary_10_1007_s12017_025_08870_0 crossref_primary_10_1016_j_arr_2023_101931 crossref_primary_10_3390_biom15010033 crossref_primary_10_1080_09638288_2024_2385732 crossref_primary_10_1038_s41420_024_02055_7 crossref_primary_10_1080_27694127_2025_2474796 crossref_primary_10_3390_biom14030358 crossref_primary_10_1002_mus_28243 crossref_primary_10_3389_fnmol_2023_1168948 crossref_primary_10_1080_00914037_2024_2399271 crossref_primary_10_3389_fncel_2022_1031153 crossref_primary_10_3390_biomedicines10112907 crossref_primary_10_1093_braincomms_fcaf292 crossref_primary_10_3390_ijms241914647 crossref_primary_10_1111_cns_13894 crossref_primary_10_7759_cureus_76760 crossref_primary_10_1016_j_nbd_2025_107077 crossref_primary_10_1016_j_smhl_2024_100521 crossref_primary_10_1111_nan_12925 crossref_primary_10_1016_j_nut_2022_111762 crossref_primary_10_1007_s00210_023_02726_9 crossref_primary_10_3389_fneur_2023_1329541 crossref_primary_10_1007_s00415_024_12449_3 crossref_primary_10_1016_j_gene_2023_147437 crossref_primary_10_3390_nu17081292 crossref_primary_10_7759_cureus_20989 crossref_primary_10_3390_cells12071016 crossref_primary_10_38079_igusabder_1557180 crossref_primary_10_1089_jpm_2022_0604 crossref_primary_10_3390_antiox11020195 crossref_primary_10_3390_ijms241914898 crossref_primary_10_3389_fnagi_2022_830346 crossref_primary_10_1016_j_neuro_2023_12_002 crossref_primary_10_17650_2222_8721_2025_15_2_37_47 crossref_primary_10_3390_cells14060464 crossref_primary_10_1080_17460441_2025_2474661 crossref_primary_10_1080_21678421_2024_2375330 crossref_primary_10_1002_alz_12760 crossref_primary_10_1007_s12017_020_08634_y crossref_primary_10_3390_metabo12121253 crossref_primary_10_2217_epi_2023_0265 crossref_primary_10_1186_s40035_022_00331_z crossref_primary_10_1155_2022_6483582 crossref_primary_10_1073_pnas_2507334122 crossref_primary_10_1093_aje_kwad099 crossref_primary_10_1134_S1819712421040164 crossref_primary_10_1080_21678421_2023_2236651 crossref_primary_10_1007_s00018_022_04217_1 crossref_primary_10_1007_s10072_024_07643_0 crossref_primary_10_1038_s41420_024_02283_x crossref_primary_10_1007_s13311_021_01064_z crossref_primary_10_1016_j_jtemb_2023_127163 crossref_primary_10_3389_fnins_2024_1422912 crossref_primary_10_1016_j_arr_2024_102414 crossref_primary_10_1186_s12883_025_04091_x crossref_primary_10_3390_ph14010029 crossref_primary_10_3389_fcimb_2022_1054190 crossref_primary_10_1186_s13023_022_02212_0 crossref_primary_10_3390_medicina60101703 crossref_primary_10_3389_fmars_2024_1370839 crossref_primary_10_2174_0113892010298545241108062449 crossref_primary_10_1007_s12152_023_09537_y crossref_primary_10_1038_s41467_024_52706_7 crossref_primary_10_2174_0929867330666230403085733 crossref_primary_10_3389_fnagi_2024_1367106 crossref_primary_10_3389_fneur_2020_598907 crossref_primary_10_3390_molecules30061211 crossref_primary_10_1016_j_jns_2024_123328 crossref_primary_10_3390_brainsci15070715 crossref_primary_10_1016_j_lfs_2025_123468 crossref_primary_10_1016_j_brainresbull_2022_08_016 crossref_primary_10_3390_cells14100680 crossref_primary_10_3389_fnmol_2022_831116 crossref_primary_10_1038_s41582_024_00991_7 crossref_primary_10_1186_s40537_025_01126_5 crossref_primary_10_1212_WNL_0000000000012279 crossref_primary_10_2196_58828 crossref_primary_10_1016_j_jpainsymman_2024_07_031 crossref_primary_10_21020_husbfd_1243670 crossref_primary_10_3389_fncom_2023_1199736 crossref_primary_10_1111_apha_13758 crossref_primary_10_1055_a_2002_5215 crossref_primary_10_1007_s12031_025_02340_9 crossref_primary_10_3390_cells10051030 crossref_primary_10_1007_s13760_024_02692_w crossref_primary_10_1038_s41588_024_01917_1 crossref_primary_10_3389_fcell_2024_1421566 crossref_primary_10_3390_antiox10060827 crossref_primary_10_1016_j_jns_2024_123210 crossref_primary_10_1038_s41420_024_01949_w crossref_primary_10_3390_biomedicines10051068 crossref_primary_10_3390_antiox12051014 crossref_primary_10_1016_j_neucli_2022_08_003 crossref_primary_10_1016_j_biopha_2022_113986 crossref_primary_10_1523_JNEUROSCI_1225_24_2024 crossref_primary_10_7759_cureus_76717 crossref_primary_10_1038_s42003_025_08579_7 crossref_primary_10_1080_21678421_2023_2260808 crossref_primary_10_1002_med_21725 crossref_primary_10_1242_dmm_050870 crossref_primary_10_1186_s40478_024_01852_6 crossref_primary_10_1007_s11064_024_04244_3 crossref_primary_10_1016_j_nbd_2024_106718 crossref_primary_10_1111_jnc_70084 crossref_primary_10_3390_biom13121784 crossref_primary_10_1007_s40136_023_00463_4 crossref_primary_10_1093_hmg_ddaf068 crossref_primary_10_1186_s12904_024_01443_1 crossref_primary_10_3389_fnmol_2024_1417961 crossref_primary_10_1186_s13024_025_00876_3 crossref_primary_10_1016_j_bbe_2022_02_001 crossref_primary_10_1007_s10787_022_00958_4 crossref_primary_10_3390_ijms23094504 crossref_primary_10_1038_s41582_022_00653_6 crossref_primary_10_1186_s40478_025_02109_6 crossref_primary_10_1016_j_bcp_2025_117301 crossref_primary_10_1016_j_envint_2022_107528 crossref_primary_10_1515_revneuro_2024_0080 crossref_primary_10_3389_fcell_2022_851613 crossref_primary_10_1016_j_cej_2025_163765 crossref_primary_10_3390_ijms241310809 crossref_primary_10_3389_fnins_2024_1399923 crossref_primary_10_3390_metabo12090837 crossref_primary_10_3389_fneur_2023_1334004 crossref_primary_10_3389_fnagi_2024_1347987 crossref_primary_10_3389_fphar_2022_881810 crossref_primary_10_1080_21678421_2023_2189911 crossref_primary_10_1016_j_bpc_2024_107230 crossref_primary_10_1016_j_neuron_2023_02_028 crossref_primary_10_1007_s00401_024_02752_8 crossref_primary_10_1016_j_jns_2025_123479 crossref_primary_10_2174_0113816128329141241205063352 crossref_primary_10_1007_s00415_024_12564_1 crossref_primary_10_1111_ene_16264 crossref_primary_10_12688_f1000research_137455_1 crossref_primary_10_1016_j_trsl_2022_08_006 crossref_primary_10_1111_ejn_70215 crossref_primary_10_3390_biom14060689 crossref_primary_10_1096_fj_202400743RR crossref_primary_10_12688_f1000research_137455_2 crossref_primary_10_3389_fimmu_2024_1445867 crossref_primary_10_1080_23279095_2024_2302833 crossref_primary_10_3390_cells12151948 crossref_primary_10_3390_s25154555 crossref_primary_10_1007_s11094_024_03134_w crossref_primary_10_1038_s41467_025_62351_3 crossref_primary_10_2174_1570159X21666230824091601 crossref_primary_10_3390_ma15010126 crossref_primary_10_3390_ijms26136183 crossref_primary_10_1007_s00221_024_06961_1 crossref_primary_10_1111_ncn3_12854 crossref_primary_10_3389_fnmol_2023_1333745 crossref_primary_10_1016_j_jns_2022_120532 crossref_primary_10_1080_21678421_2025_2536027 crossref_primary_10_1007_s13311_023_01376_2 crossref_primary_10_1111_jnc_16160 crossref_primary_10_1007_s00401_023_02611_y crossref_primary_10_3389_fnins_2021_679199 crossref_primary_10_1186_s40580_024_00426_5 crossref_primary_10_3390_neurolint15020035 crossref_primary_10_3390_biom15081130 crossref_primary_10_1016_j_brainres_2024_149348 crossref_primary_10_1212_NXG_0000000000200188 crossref_primary_10_1007_s11869_024_01612_4 crossref_primary_10_3390_genes16060623 crossref_primary_10_1016_j_ijbiomac_2025_145645 crossref_primary_10_3389_ebm_2025_10575 crossref_primary_10_3390_ijms21217923 crossref_primary_10_3390_cells10113005 crossref_primary_10_3390_ijms25137059 crossref_primary_10_3390_diagnostics11020231 crossref_primary_10_1038_s41467_025_62482_7 crossref_primary_10_3389_fneur_2024_1393261 crossref_primary_10_3390_ph15010094 crossref_primary_10_1590_0034_7167_2024_0297pt crossref_primary_10_1002_mabi_202400150 crossref_primary_10_1111_ncn3_12880 crossref_primary_10_1007_s11011_025_01616_8 crossref_primary_10_1002_nep3_26 crossref_primary_10_1038_s41467_024_51676_0 crossref_primary_10_1016_j_jor_2024_10_040 crossref_primary_10_1017_S1478951522000542 crossref_primary_10_1016_j_arr_2024_102357 crossref_primary_10_1177_10499091241266985 crossref_primary_10_26508_lsa_202402853 crossref_primary_10_1016_j_arr_2024_102233 crossref_primary_10_1016_j_arr_2024_102594 crossref_primary_10_1093_hmg_ddaf020 crossref_primary_10_3390_biomedicines12051083 crossref_primary_10_1016_j_bnd_2024_12_003 crossref_primary_10_1016_j_jpsychires_2024_08_030 crossref_primary_10_3390_ani13193126 crossref_primary_10_1080_21678421_2024_2400522 crossref_primary_10_1080_17582024_2025_2554382 crossref_primary_10_1186_s12920_023_01441_x crossref_primary_10_7759_cureus_48691 crossref_primary_10_1016_j_nbd_2024_106639 crossref_primary_10_1109_TCBBIO_2025_3552631 crossref_primary_10_1016_j_neurol_2023_07_011 crossref_primary_10_1016_j_nbd_2025_106815 crossref_primary_10_1002_1873_3468_14729 crossref_primary_10_1007_s00415_024_12699_1 crossref_primary_10_4103_1673_5374_385283 crossref_primary_10_1016_j_nicl_2023_103505 crossref_primary_10_1080_24735132_2025_2506308 crossref_primary_10_3389_fnins_2024_1401706 crossref_primary_10_4103_1673_5374_385285 crossref_primary_10_1002_glia_24531 crossref_primary_10_1016_j_expneurol_2024_115057 crossref_primary_10_2147_IJN_S537566 crossref_primary_10_1007_s00415_024_12774_7 crossref_primary_10_3390_biomedicines12102362 crossref_primary_10_1016_j_ijbiomac_2023_123259 crossref_primary_10_1021_acschemneuro_4c00593 crossref_primary_10_3389_fcvm_2021_715842 crossref_primary_10_1016_j_ijscr_2025_111585 crossref_primary_10_1016_j_neubiorev_2022_104896 crossref_primary_10_1038_s41467_022_32939_0 crossref_primary_10_3389_ebm_2025_10593 crossref_primary_10_3389_fgene_2021_811699 crossref_primary_10_1007_s00429_024_02884_3 crossref_primary_10_3389_fpsyt_2023_1291115 crossref_primary_10_1002_cmdc_202400244 crossref_primary_10_1016_j_jddst_2024_106292 crossref_primary_10_3389_fncel_2021_652593 crossref_primary_10_1111_ene_15010 crossref_primary_10_3389_fphar_2022_859516 crossref_primary_10_3390_diagnostics11081365 crossref_primary_10_4103_1673_5374_386406 crossref_primary_10_7759_cureus_45489 crossref_primary_10_3390_genes16020135 crossref_primary_10_1186_s11658_024_00633_2 crossref_primary_10_1109_ACCESS_2022_3164075 crossref_primary_10_3389_fnagi_2022_827500 crossref_primary_10_1016_j_heliyon_2024_e40696 crossref_primary_10_1007_s11033_022_07647_z crossref_primary_10_7759_cureus_56023 crossref_primary_10_3390_computation11110225 crossref_primary_10_1590_0034_7167_2024_0297 crossref_primary_10_1002_brb3_70018 crossref_primary_10_3390_jpm11070671 crossref_primary_10_1016_S1474_4422_24_00517_9 crossref_primary_10_3390_brainsci15040329 crossref_primary_10_1016_j_biopha_2023_114378 crossref_primary_10_1021_acsabm_5c00096 crossref_primary_10_28957_rcmfr_413 crossref_primary_10_1007_s11033_025_10542_y crossref_primary_10_1016_j_neurol_2024_01_006 crossref_primary_10_1007_s13577_025_01178_y crossref_primary_10_1186_s41983_022_00531_4 crossref_primary_10_1016_j_jgg_2025_05_008 crossref_primary_10_1016_j_mcn_2023_103834 crossref_primary_10_1002_brb3_70484 crossref_primary_10_1016_j_mrrev_2024_108518 crossref_primary_10_1080_21678421_2025_2539900 crossref_primary_10_13005_bbra_3226 crossref_primary_10_3390_cells14100715 crossref_primary_10_1186_s13148_025_01820_4 crossref_primary_10_3390_biology13090719 crossref_primary_10_3390_ijms231911734 crossref_primary_10_1371_journal_pgen_1011518 crossref_primary_10_1111_ene_70088 crossref_primary_10_7759_cureus_50602 crossref_primary_10_1155_2023_5864391 crossref_primary_10_3389_fnins_2023_1251228 crossref_primary_10_3390_cells10092438 crossref_primary_10_3389_fnhum_2025_1539081 crossref_primary_10_3390_app14041545 crossref_primary_10_3390_neuroglia6010009 crossref_primary_10_1021_acschemneuro_4c00664 crossref_primary_10_1044_2025_AJSLP_24_00489 crossref_primary_10_3389_fimmu_2024_1360068 crossref_primary_10_1093_brain_awab240 crossref_primary_10_1186_s13024_025_00811_6 crossref_primary_10_1186_s40035_023_00380_y crossref_primary_10_3390_ijms25073995 crossref_primary_10_1186_s12916_024_03293_3 crossref_primary_10_3390_metabo12111096 crossref_primary_10_3390_biom13111582 crossref_primary_10_1038_s41593_025_02033_x crossref_primary_10_1002_acn3_52066 crossref_primary_10_1016_j_neures_2021_07_005 crossref_primary_10_1016_j_nbd_2024_106430 crossref_primary_10_1016_j_nbd_2025_106851 crossref_primary_10_2174_0113892037335036241007043530 crossref_primary_10_1080_10400435_2025_2497865 crossref_primary_10_1111_ene_16140 crossref_primary_10_1016_j_mito_2022_02_004 crossref_primary_10_1134_S0362119721080016 crossref_primary_10_3390_genes15030309 crossref_primary_10_1002_mus_27935 crossref_primary_10_1007_s12640_022_00564_w crossref_primary_10_1080_21678421_2024_2439454 crossref_primary_10_3390_ijms251910392 crossref_primary_10_1080_21642850_2024_2396137 crossref_primary_10_3389_fnins_2025_1599492 crossref_primary_10_3390_diagnostics11040701 crossref_primary_10_1016_j_freeradbiomed_2021_11_031 crossref_primary_10_1038_s41598_023_45593_3 crossref_primary_10_3390_cells12111523 crossref_primary_10_1002_ana_26009 crossref_primary_10_3390_ijms26104904 crossref_primary_10_3390_antiox13091062 crossref_primary_10_1016_j_nantod_2024_102169 crossref_primary_10_3389_fmolb_2021_794646 crossref_primary_10_1007_s11055_023_01365_0 crossref_primary_10_7759_cureus_80329 crossref_primary_10_1016_j_bbagen_2024_130634 crossref_primary_10_1038_s41540_025_00501_5 crossref_primary_10_1177_26331055221087740 crossref_primary_10_3390_brainsci13060911 crossref_primary_10_1016_j_cbpa_2021_05_007 crossref_primary_10_1111_jnc_70079 crossref_primary_10_1016_j_addr_2024_115274 crossref_primary_10_1038_s41598_021_95338_3 crossref_primary_10_1080_21678421_2023_2255622 crossref_primary_10_3389_fimmu_2022_1059994 crossref_primary_10_1055_s_0043_1775595 crossref_primary_10_3390_ijms22158042 crossref_primary_10_1007_s00415_022_10971_w crossref_primary_10_3389_fnins_2025_1582539 crossref_primary_10_1093_brain_awae331 crossref_primary_10_1016_j_clinph_2022_11_005 crossref_primary_10_4274_tod_galenos_2024_37880 crossref_primary_10_1016_j_lfs_2021_120156 crossref_primary_10_1002_acn3_52087 crossref_primary_10_3390_antiox12010118 crossref_primary_10_3390_ijms24010704 crossref_primary_10_1038_s41746_025_01654_7 crossref_primary_10_1038_s43587_023_00464_4 crossref_primary_10_1111_ene_15584 crossref_primary_10_1002_glia_24278 crossref_primary_10_1016_j_nbd_2025_106871 crossref_primary_10_1007_s00702_025_02971_7 crossref_primary_10_1038_s41598_022_19911_0 crossref_primary_10_1021_acsptsci_5c00153 crossref_primary_10_1016_j_jddst_2023_104868 crossref_primary_10_1080_21678421_2024_2403306 crossref_primary_10_2147_EB_S516393 crossref_primary_10_1007_s00415_023_12141_y crossref_primary_10_3390_biom13101444 crossref_primary_10_1007_s11548_024_03099_x crossref_primary_10_3389_fimmu_2024_1345625 crossref_primary_10_1080_21678421_2024_2403305 crossref_primary_10_3389_fnmol_2022_1005112 crossref_primary_10_3390_ijms23052400 crossref_primary_10_1136_jmg_2022_108477 crossref_primary_10_1159_000525091 crossref_primary_10_1038_s12276_021_00709_5 crossref_primary_10_1111_ene_16206 crossref_primary_10_2196_63004 crossref_primary_10_1186_s40001_024_01987_1 crossref_primary_10_3390_medicina61091694 crossref_primary_10_3390_ijms242417339 crossref_primary_10_1016_j_tice_2025_102780 crossref_primary_10_1111_ene_16201 crossref_primary_10_1097_WCO_0000000000001294 crossref_primary_10_1016_j_bbamcr_2025_119954 crossref_primary_10_1186_s41983_024_00867_z crossref_primary_10_1007_s12264_025_01439_8 crossref_primary_10_7759_cureus_67378 crossref_primary_10_1080_21678421_2024_2359556 crossref_primary_10_3389_fneur_2021_788462 crossref_primary_10_1016_j_neures_2023_09_002 crossref_primary_10_3390_ijms25137006 crossref_primary_10_3389_fneur_2024_1396002 crossref_primary_10_1002_brb3_70571 crossref_primary_10_3390_ijms241310717 crossref_primary_10_3389_fncel_2023_1247297 crossref_primary_10_3390_cells12060933 crossref_primary_10_1044_2021_JSLHR_21_00396 crossref_primary_10_3390_biomedicines10040819 crossref_primary_10_35440_hutfd_1291224 crossref_primary_10_3390_diagnostics13020288 crossref_primary_10_1038_s41591_025_03890_6 crossref_primary_10_3390_ncrna7020036 crossref_primary_10_1097_CND_0000000000000520 crossref_primary_10_3390_cells12111536 crossref_primary_10_3390_medicina61091685 crossref_primary_10_1016_j_ymthe_2022_04_018 crossref_primary_10_7759_cureus_68579 crossref_primary_10_1097_WCO_0000000000001164 crossref_primary_10_3389_fnmol_2022_867935 crossref_primary_10_3390_cells13060485 crossref_primary_10_3390_biomimetics9060362 crossref_primary_10_1016_j_socscimed_2024_117063 crossref_primary_10_1080_21678421_2025_2523945 crossref_primary_10_1044_2022_AJSLP_22_00046 crossref_primary_10_1080_07853890_2022_2153162 crossref_primary_10_1080_17460441_2021_1915979 crossref_primary_10_1097_MD_0000000000031446 crossref_primary_10_1109_TBME_2024_3401713 crossref_primary_10_4103_2045_9912_390249 crossref_primary_10_1093_brain_awad291 crossref_primary_10_3390_ijms23052580 crossref_primary_10_1111_ncn3_70029 crossref_primary_10_1002_pnp_12005 crossref_primary_10_1016_j_cis_2022_102824 crossref_primary_10_1016_j_compbiomed_2023_107688 crossref_primary_10_1002_ohn_1229 crossref_primary_10_1080_21678421_2024_2403299 crossref_primary_10_1007_s11033_025_10463_w crossref_primary_10_1097_MS9_0000000000001319 crossref_primary_10_1080_21678421_2024_2407412 crossref_primary_10_1038_s41598_023_49424_3 crossref_primary_10_31083_j_jin2304077 crossref_primary_10_1002_ccr3_8544 crossref_primary_10_1038_s41598_023_30871_x crossref_primary_10_1016_j_bbr_2024_115280 crossref_primary_10_1016_j_neuroscience_2025_09_029 crossref_primary_10_3390_cells11244038 crossref_primary_10_1016_j_psycr_2025_100255 crossref_primary_10_3390_jpm13091396 crossref_primary_10_1186_s12883_025_04245_x crossref_primary_10_1016_j_nbd_2022_105768 crossref_primary_10_1109_ACCESS_2023_3326720 crossref_primary_10_1002_mus_70023 crossref_primary_10_3390_biomedicines11102629 crossref_primary_10_1186_s40035_024_00460_7 crossref_primary_10_1016_j_arr_2023_101855 crossref_primary_10_1016_j_expneurol_2022_114143 crossref_primary_10_1007_s12035_025_04725_8 crossref_primary_10_3390_cells10071789 crossref_primary_10_1007_s13311_023_01424_x crossref_primary_10_1016_j_arr_2022_101790 crossref_primary_10_3390_ijms25042268 crossref_primary_10_1007_s11606_025_09831_w crossref_primary_10_3389_fncel_2023_1134090 crossref_primary_10_1007_s12035_023_03857_z crossref_primary_10_1016_j_isci_2024_109166 crossref_primary_10_1016_j_molliq_2025_127938 crossref_primary_10_3390_ijms22063007 crossref_primary_10_1097_MS9_0000000000003645 crossref_primary_10_57197_JDR_2024_0119 crossref_primary_10_1007_s10787_024_01492_1 crossref_primary_10_1016_j_celrep_2025_115959 crossref_primary_10_1111_ene_16400 crossref_primary_10_1038_s41598_024_80851_y crossref_primary_10_1038_s41419_023_05643_0 crossref_primary_10_1111_ejn_16226 crossref_primary_10_1016_j_nbd_2022_105653 crossref_primary_10_1080_21678421_2025_2477732 crossref_primary_10_1186_s13023_024_03057_5 crossref_primary_10_3389_fnagi_2022_907122 crossref_primary_10_1002_jnr_70006 crossref_primary_10_1042_BST20230341 crossref_primary_10_1186_s40478_022_01314_x crossref_primary_10_3390_jcm13092507 crossref_primary_10_1007_s12031_023_02169_0 crossref_primary_10_3390_cells10092394 crossref_primary_10_1007_s00018_021_04070_8 crossref_primary_10_1016_j_chemosphere_2024_143180 crossref_primary_10_3390_ijms22126352 crossref_primary_10_3390_genes16030309 crossref_primary_10_1016_j_mex_2024_102765 crossref_primary_10_3390_cells13070648 crossref_primary_10_1016_j_clinph_2022_08_008 crossref_primary_10_1080_1750743X_2025_2554566 crossref_primary_10_12688_f1000research_138436_1 crossref_primary_10_3389_fneur_2021_783122 crossref_primary_10_12688_f1000research_138436_2 crossref_primary_10_1080_0964704X_2024_2380635 crossref_primary_10_1080_21678421_2024_2351185 crossref_primary_10_1080_21678421_2025_2454923 crossref_primary_10_37349_ent_2025_1004104 crossref_primary_10_17816_ACEN_1070 crossref_primary_10_1007_s11940_023_00757_4 crossref_primary_10_3390_healthcare11111641 crossref_primary_10_1038_s41598_025_89080_3 crossref_primary_10_3390_cells12060971 crossref_primary_10_1371_journal_pone_0320788 crossref_primary_10_3389_fneur_2023_1258224 crossref_primary_10_1159_000530974 crossref_primary_10_3390_healthcare12060627 crossref_primary_10_1007_s00415_021_10521_w crossref_primary_10_1242_dmm_052148 crossref_primary_10_1111_imr_13083 crossref_primary_10_1098_rsob_240073 crossref_primary_10_1016_j_jmb_2024_168751 crossref_primary_10_1016_j_immuni_2025_02_024 crossref_primary_10_3389_frma_2023_1067981 crossref_primary_10_7759_cureus_37814 crossref_primary_10_1631_jzus_B2300457 crossref_primary_10_3389_fnins_2024_1505029 crossref_primary_10_1212_WNL_0000000000209925 crossref_primary_10_3390_biom12091200 crossref_primary_10_3390_brainsci11030369 crossref_primary_10_1016_j_phanu_2024_100406 crossref_primary_10_1080_21678421_2025_2511119 crossref_primary_10_3390_cells11193093 crossref_primary_10_3390_ijms25115707 crossref_primary_10_3389_fdgth_2024_1476293 crossref_primary_10_3390_brainsci12030345 crossref_primary_10_1038_s44319_024_00140_7 crossref_primary_10_1055_s_0045_1804922 crossref_primary_10_1002_brb3_3243 crossref_primary_10_1007_s12035_024_04143_2 crossref_primary_10_1007_s13596_022_00631_9 crossref_primary_10_4103_NRR_NRR_D_23_01359 crossref_primary_10_5812_ans_131625 crossref_primary_10_3390_jcm12227045 crossref_primary_10_1111_ejn_16370 crossref_primary_10_7759_cureus_51048 crossref_primary_10_1186_s12874_023_02051_y crossref_primary_10_3390_ijms222011224 crossref_primary_10_3390_ijms23169328 crossref_primary_10_3390_ph18040497 crossref_primary_10_1038_s42003_025_08561_3 crossref_primary_10_1016_j_ebiom_2025_105845 crossref_primary_10_1038_s41598_021_02041_4 crossref_primary_10_4103_NRR_NRR_D_24_00286 crossref_primary_10_1136_bmjopen_2022_064086 crossref_primary_10_3390_ijerph20043310 crossref_primary_10_1186_s13024_022_00591_3 crossref_primary_10_3390_genes15101342 crossref_primary_10_3390_ph16020311 crossref_primary_10_1097_CND_0000000000000471 crossref_primary_10_1186_s13024_024_00774_0 crossref_primary_10_1111_scs_70108 crossref_primary_10_3389_fnmol_2024_1386735 crossref_primary_10_1002_cbf_3692 crossref_primary_10_1515_biol_2022_0842 crossref_primary_10_1080_17483107_2025_2516628 crossref_primary_10_3349_ymj_2024_0145 crossref_primary_10_1080_01616412_2024_2362578 crossref_primary_10_3390_ijms222112078 crossref_primary_10_1007_s12031_025_02317_8 crossref_primary_10_3390_biomedicines11112967 crossref_primary_10_1186_s43556_023_00142_2 crossref_primary_10_1002_hsr2_71282 crossref_primary_10_3390_cells11213431 crossref_primary_10_1016_j_clinph_2021_05_016 crossref_primary_10_3390_ijms252413424 crossref_primary_10_1016_j_socscimed_2024_117345 crossref_primary_10_1080_21678421_2023_2284899 crossref_primary_10_3390_muscles2010006 crossref_primary_10_1016_j_clnesp_2025_01_042 crossref_primary_10_1155_2022_1789946 crossref_primary_10_1186_s12904_024_01524_1 crossref_primary_10_3390_cells10040961 crossref_primary_10_1007_s00415_024_12528_5 crossref_primary_10_3390_genes14020325 crossref_primary_10_3390_cells12050736 crossref_primary_10_1007_s12035_024_04671_x crossref_primary_10_3390_diagnostics11040624 crossref_primary_10_1111_jnc_70204 crossref_primary_10_1002_dvdy_333 crossref_primary_10_1186_s40537_024_00951_4
Cites_doi	10.1212/WNL.51.6.1546 10.1038/ng.442 10.1093/brain/115.2.495 10.1186/s13024-019-0327-3 10.3727/096368912X633770 10.1126/science.1165942 10.3389/fneur.2019.00260 10.1038/nature20413 10.1212/WNL.0b013e3181b6bbbd 10.1126/science.1134108 10.1038/gim.2016.107 10.1016/j.neurobiolaging.2015.08.009 10.1016/j.nbd.2017.02.004 10.1038/nrdp.2017.85 10.1016/S0140-6736(17)31287-4 10.3109/21678421.2015.1030430 10.1056/NEJM199403033300901 10.1080/21678421.2019.1632346 10.1016/S1474-4422(18)30089-9 10.1038/362059a0 10.1038/nrneurol.2011.153 10.1111/j.1468-1331.2011.03501.x 10.1080/21678421.2017.1386687 10.1136/jnnp.2009.183525 10.15252/embj.201694401 10.1093/hmg/dds199 10.1080/146608200300079536 10.1212/01.WNL.0000134608.83927.B1 10.1080/21678421.2017.1369125 10.1001/jamaneurol.2019.2044 10.1007/s00415-019-09648-8 10.1016/S1474-4422(10)70195-2 10.1007/s00401-016-1586-5 10.1001/jamaneurol.2014.62 10.1016/j.nmd.2016.04.004 10.1136/jnnp.2010.235952 10.1016/j.neurobiolaging.2011.10.029 10.1016/j.neuron.2018.02.027 10.1056/NEJMra1603471 10.1016/j.neuron.2011.09.011 10.1002/ana.22380 10.1126/science.1166066 10.1038/nature09320 10.1212/01.wnl.0000345041.83406.a2 10.1001/archneur.57.1.109 10.1212/WNL.0000000000004029 10.1016/S0140-6736(96)91680-3 10.1093/brain/awx370 10.1212/WNL.0b013e31821f445b 10.1016/j.clinph.2020.04.005 10.1136/jnnp.2010.207464 10.1126/science.aaa3650 10.1016/S1474-4422(18)30404-6 10.1038/ng.132 10.1016/S1474-4422(07)70265-X 10.1007/s00415-006-0195-y 10.1016/S1474-4422(17)30115-1 10.1016/S1474-4422(14)70129-2 10.1080/14653240802549470 10.3109/17482961003610853 10.1093/brain/124.9.1708 10.1038/nature10353 10.1136/jnnp.2010.208413 10.1016/j.clinph.2007.09.143 10.1001/archneurol.2011.250 10.1136/jnnp-2017-316605 10.1212/WNL.0000000000003686 10.1111/j.1742-4658.2010.07643.x 10.1172/JCI25424 10.1126/science.1154584 10.1016/j.neuron.2011.09.010 10.1080/21678421.2016.1267768 10.1093/brain/awr195 10.1136/jnnp.2009.186833 10.1212/WNL.0000000000000792 10.1002/mus.24244 10.1016/S1474-4422(16)30199-5 10.1016/j.jns.2007.05.016 10.1038/nature08971 10.1016/j.neuron.2016.04.006 10.1038/nrneurol.2013.203 10.1038/nn.4000 10.1016/j.neuron.2010.11.036
ContentType	Journal Article
Copyright	2020 The Authors. published by John Wiley & Sons Ltd on behalf of European Academy of Neurology 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. 2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: 2020 The Authors. published by John Wiley & Sons Ltd on behalf of European Academy of Neurology – notice: 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. – notice: 2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	24P AAYXX CITATION NPM 7TK 7U7 C1K K9. 7X8 5PM
DOI	10.1111/ene.14393
DatabaseName	Wiley Online Library Open Access CrossRef PubMed Neurosciences Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef PubMed ProQuest Health & Medical Complete (Alumni) Toxicology Abstracts Neurosciences Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic
DatabaseTitleList	PubMed MEDLINE - Academic CrossRef ProQuest Health & Medical Complete (Alumni)
Database_xml	– sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
DocumentTitleAlternate	ALS: a clinical review
EISSN	1468-1331
EndPage	1929
ExternalDocumentID	PMC7540334 32526057 10_1111_ene_14393 ENE14393
Genre	reviewArticle Research Support, Non-U.S. Gov't Journal Article Review
GrantInformation_xml	– fundername: KU Leuven funderid: C1‐C14‐17‐107 – fundername: the Fund for Scientific Research Flanders (FWO‐Flanders) – fundername: Een Hart voor ALS – fundername: Flanders Innovation and Enterpreneurship (IWT grants Project MinE and iPSCAF) – fundername: ’ – fundername: the Alzheimer Research Foundation funderid: SAO‐FRA 2017/023 – fundername: the Flemish Government initiated Flanders Impulse Program on Networks for Dementia Research funderid: VIND 135043 – fundername: Valéry Perrier Race against ALS Fund – fundername: the Belgian National Lottery – fundername: the European Union’s Horizon 2020 research and innovation programme funderid: 755094 – fundername: ' – fundername: the Alzheimer Research Foundation grantid: SAO-FRA 2017/023 – fundername: the Flemish Government initiated Flanders Impulse Program on Networks for Dementia Research grantid: VIND 135043 – fundername: the European Union's Horizon 2020 research and innovation programme grantid: 755094 – fundername: the Fund for Scientific Research Flanders (FWO-Flanders) – fundername: KU Leuven grantid: C1-C14-17-107 – fundername: ; – fundername: the European Union’s Horizon 2020 research and innovation programme grantid: 755094 – fundername: ; grantid: C1‐C14‐17‐107 – fundername: the Alzheimer Research Foundation grantid: SAO‐FRA 2017/023
GroupedDBID	--- .3N .GA .Y3 05W 0R~ 10A 169 1OB 1OC 24P 29G 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 8FI 8FJ 8UM 930 A01 A03 AAESR AAEVG AAHHS AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIVO ABJNI ABPVW ABUWG ABXGK ACAHQ ACBWZ ACCFJ ACCMX ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADPDF ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFGKR AFKRA AFPWT AFRAH AFWVQ AFZJQ AHMBA AIACR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BENPR BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN ESX EX3 F00 F5P FEDTE FUBAC FYBCS FYUFA G-S G.N GODZA H.X HF~ HMCUK HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD OVEED P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIG RIWAO RJQFR ROL RPM RX1 SAMSI SUPJJ TEORI UB1 UKHRP W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AGQPQ AGXDD AIDQK AIDYY AIQQE CITATION GROUPED_DOAJ O8X PHGZM WIN NPM 7TK 7U7 C1K K9. 7X8 5PM
ID	FETCH-LOGICAL-c5093-ecf9ec208de5baea93ca139ecebe2ca0a2872cc315d6f6123e67b0013c24e52e3
IEDL.DBID	24P
ISICitedReferencesCount	743
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000545989200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1351-5101 1468-1331
IngestDate	Tue Nov 04 01:57:57 EST 2025 Sun Nov 09 13:18:47 EST 2025 Sat Nov 29 14:53:04 EST 2025 Wed Feb 19 02:30:02 EST 2025 Sat Nov 29 05:12:47 EST 2025 Tue Nov 18 21:12:44 EST 2025 Wed Jan 22 16:32:05 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	10
Keywords	TDP-43 pathology amyotrophic lateral sclerosis sporadic and familial ALS
Language	English
License	Attribution-NonCommercial 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c5093-ecf9ec208de5baea93ca139ecebe2ca0a2872cc315d6f6123e67b0013c24e52e3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ORCID	0000-0001-8247-1866 0000-0002-4010-2357
OpenAccessLink	https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fene.14393
PMID	32526057
PQID	2442707176
PQPubID	1066358
PageCount	12
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_7540334 proquest_miscellaneous_2412989169 proquest_journals_2442707176 pubmed_primary_32526057 crossref_primary_10_1111_ene_14393 crossref_citationtrail_10_1111_ene_14393 wiley_primary_10_1111_ene_14393_ENE14393
PublicationCentury	2000
PublicationDate	October 2020
PublicationDateYYYYMMDD	2020-10-01
PublicationDate_xml	– month: 10 year: 2020 text: October 2020
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: Oxford – name: Hoboken
PublicationTitle	European journal of neurology
PublicationTitleAlternate	Eur J Neurol
PublicationYear	2020
Publisher	John Wiley & Sons, Inc John Wiley and Sons Inc
Publisher_xml	– name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc
References	2010; 11 1994; 330 2011; 477 2004; 63 2017; 7 2015; 36 2009; 41 2017; 3 2015; 347 2019; 10 2010; 466 2017; 88 2017; 46 2010; 465 2019; 14 2017; 390 2006; 253 2012; 19 2000; 1 2018; 89 2008; 265 1993; 362 2016; 35 2013; 9 1996; 347 2009; 11 2010; 68 2016; 90 2020; 131 2000; 57 2011; 70 2010; 277 2008; 319 2011; 72 1992; 115 2016; 87 2008; 119 2007; 6 2014; 13 2011; 68 1998; 51 2014; 50 2009; 323 2012; 21 2010; 9 2018; 141 2001; 124 2015; 16 2015; 18 2019; 76 2011; 82 2011; 76 2020; 267 2006; 314 2010; 81 2006; 116 2017; 377 2014; 83 2015; 7 2016; 15 2012; 33 2011; 134 2011; 7 2018; 19 2018; 17 2009; 73 2016; 539 2009; 72 2017; 16 2016; 132 2016 2017; 19 2017; 18 2020; 21 2008; 40 2018; 97 2016; 26 2014; 71 2017; 105 e_1_2_13_24_1 e_1_2_13_49_1 e_1_2_13_26_1 e_1_2_13_47_1 e_1_2_13_68_1 e_1_2_13_20_1 e_1_2_13_45_1 e_1_2_13_66_1 e_1_2_13_87_1 e_1_2_13_22_1 e_1_2_13_43_1 e_1_2_13_64_1 e_1_2_13_85_1 e_1_2_13_8_1 e_1_2_13_41_1 e_1_2_13_62_1 e_1_2_13_60_1 e_1_2_13_83_1 e_1_2_13_6_1 e_1_2_13_81_1 e_1_2_13_19_1 e_1_2_13_13_1 e_1_2_13_36_1 e_1_2_13_59_1 e_1_2_13_15_1 e_1_2_13_57_1 Marin B (e_1_2_13_17_1) 2017; 46 e_1_2_13_32_1 e_1_2_13_55_1 e_1_2_13_78_1 e_1_2_13_11_1 e_1_2_13_34_1 e_1_2_13_53_1 e_1_2_13_76_1 e_1_2_13_51_1 e_1_2_13_74_1 e_1_2_13_30_1 e_1_2_13_70_1 Hinchcliffe M (e_1_2_13_80_1) 2017; 7 e_1_2_13_4_1 e_1_2_13_2_1 e_1_2_13_88_1 e_1_2_13_29_1 Ingre C (e_1_2_13_38_1) 2015; 7 e_1_2_13_25_1 e_1_2_13_48_1 e_1_2_13_27_1 e_1_2_13_46_1 e_1_2_13_69_1 e_1_2_13_21_1 e_1_2_13_44_1 e_1_2_13_67_1 e_1_2_13_23_1 e_1_2_13_42_1 e_1_2_13_65_1 e_1_2_13_86_1 e_1_2_13_9_1 e_1_2_13_40_1 e_1_2_13_63_1 e_1_2_13_84_1 e_1_2_13_7_1 e_1_2_13_61_1 e_1_2_13_82_1 e_1_2_13_18_1 e_1_2_13_39_1 e_1_2_13_14_1 e_1_2_13_35_1 e_1_2_13_16_1 e_1_2_13_37_1 e_1_2_13_58_1 e_1_2_13_79_1 e_1_2_13_10_1 e_1_2_13_31_1 e_1_2_13_77_1 e_1_2_13_12_1 e_1_2_13_33_1 e_1_2_13_54_1 e_1_2_13_75_1 e_1_2_13_52_1 e_1_2_13_73_1 e_1_2_13_50_1 e_1_2_13_71_1 (e_1_2_13_56_1) 2016 Steinacker P (e_1_2_13_72_1) 2016; 87 e_1_2_13_5_1 e_1_2_13_3_1 e_1_2_13_89_1 e_1_2_13_28_1
References_xml	– volume: 1 start-page: 293 year: 2000 end-page: 299 article-title: El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis publication-title: Amyotroph Lateral Scler Other Motor Neuron Disord – volume: 21 start-page: S57 year: 2012 end-page: S63 article-title: Feasibility, safety, and preliminary proof of principles of autologous neural stem cell treatment combined with T‐cell vaccination for ALS patients publication-title: Cell Transplant – volume: 7 start-page: 61 year: 2017 end-page: 70 article-title: Riluzole: real‐world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis publication-title: Degener Neurol Neuromuscul Dis – volume: 82 start-page: 740 year: 2011 end-page: 746 article-title: Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study publication-title: J Neurol Neurosurg Psychiatry – volume: 6 start-page: 994 year: 2007 end-page: 1003 article-title: Cognitive impairment in amyotrophic lateral sclerosis publication-title: Lancet Neurol – volume: 26 start-page: 350 year: 2016 end-page: 353 article-title: Myasthenia gravis with muscle specific kinase antibodies mimicking amyotrophic lateral sclerosis publication-title: Neuromuscul Disord – volume: 362 start-page: 59 year: 1993 end-page: 62 article-title: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis publication-title: Nature – volume: 73 start-page: 805 year: 2009 end-page: 811 article-title: ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration publication-title: Neurology – volume: 253 start-page: 1642 year: 2006 end-page: 1643 article-title: Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London publication-title: J Neurol – volume: 347 start-page: 1425 year: 1996 end-page: 1431 article-title: Dose‐ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II publication-title: Lancet – volume: 132 start-page: 159 year: 2016 end-page: 173 article-title: Inside out: the role of nucleocytoplasmic transport in ALS and FTLD publication-title: Acta Neuropathol – volume: 88 start-page: 991 year: 2017 end-page: 999 article-title: Genetic testing in ALS: a survey of current practices publication-title: Neurology – volume: 377 start-page: 162 year: 2017 end-page: 172 article-title: Amyotrophic lateral sclerosis publication-title: N Engl J Med – volume: 71 start-page: 553 year: 2014 end-page: 561 article-title: Value of fluorodeoxyglucose‐positron‐emission tomography in amyotrophic lateral sclerosis: a prospective study publication-title: JAMA Neurol – volume: 277 start-page: 2268 year: 2010 end-page: 2281 article-title: Nuclear factor TDP‐43 can affect selected microRNA levels publication-title: FEBS J – volume: 14 start-page: 27 year: 2019 article-title: Dynactin1 depletion leads to neuromuscular synapse instability and functional abnormalities publication-title: Mol Neurodegener – volume: 51 start-page: 1546 year: 1998 end-page: 1554 article-title: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria publication-title: Neurology – volume: 11 start-page: 439 year: 2010 end-page: 442 article-title: The sex ratio in amyotrophic lateral sclerosis: a population based study publication-title: Amyotroph Lateral Scler – volume: 35 start-page: 1656 year: 2016 end-page: 1676 article-title: The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy publication-title: EMBO J – volume: 82 start-page: 853 year: 2011 end-page: 854 article-title: Concordance between site of onset and limb dominance in amyotrophic lateral sclerosis publication-title: J Neurol Neurosurg Psychiatry – volume: 11 start-page: 18 year: 2009 end-page: 25 article-title: Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow‐derived hematopoietic stem cell transplantation: a 1‐year follow‐up publication-title: Cytotherapy – volume: 41 start-page: 1083 year: 2009 end-page: 1087 article-title: Genome‐wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis publication-title: Nat Genet – volume: 18 start-page: 471 year: 2017 end-page: 474 article-title: July 2017 ENCALS statement on edaravone publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 88 start-page: 2302 year: 2017 end-page: 2309 article-title: Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease publication-title: Neurology – volume: 72 start-page: 257 year: 2011 end-page: 268 article-title: A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21‐linked ALS‐FTD publication-title: Neuron – volume: 40 start-page: 572 year: 2008 end-page: 574 article-title: TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis publication-title: Nat Genet – volume: 21 start-page: 3776 year: 2012 end-page: 3784 article-title: Evidence for an oligogenic basis of amyotrophic lateral sclerosis publication-title: Hum Mol Genet – volume: 57 start-page: 109 year: 2000 end-page: 113 article-title: Amyotrophic lateral sclerosis mimic syndromes: a population‐based study publication-title: Arch Neurol – volume: 7 start-page: 639 year: 2011 end-page: 649 article-title: Clinical diagnosis and management of amyotrophic lateral sclerosis publication-title: Nat Rev Neurol – volume: 46 start-page: 57 year: 2017 end-page: 74 article-title: Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta‐analysis publication-title: Int J Epidemiol – volume: 7 start-page: 181 year: 2015 end-page: 193 article-title: Risk factors for amyotrophic lateral sclerosis publication-title: Clin Epidemiol – volume: 10 start-page: 260 year: 2019 article-title: Pathological crying and laughing in motor neuron disease: pathobiology, screening, intervention publication-title: Front Neurol – volume: 16 start-page: 172 year: 2015 end-page: 179 article-title: Validation of the Edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen (ECAS): a cognitive tool for motor disorders publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 82 start-page: 549 year: 2011 end-page: 551 article-title: Detecting fasciculations in amyotrophic lateral sclerosis: duration of observation required publication-title: J Neurol Neurosurg Psychiatry – volume: 323 start-page: 1208 year: 2009 end-page: 1211 article-title: Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6 publication-title: Science – volume: 465 start-page: 223 year: 2010 end-page: 226 article-title: Mutations of optineurin in amyotrophic lateral sclerosis publication-title: Nature – volume: 105 start-page: 283 year: 2017 end-page: 299 article-title: Neurobiology of axonal transport defects in motor neuron diseases: opportunities for translational research? publication-title: Neurobiol Dis – volume: 9 start-page: 617 year: 2013 end-page: 628 article-title: The epidemiology of ALS: a conspiracy of genes, environment and time publication-title: Nat Rev Neurol – volume: 134 start-page: 2582 year: 2011 end-page: 2594 article-title: Motor neuron dysfunction in frontotemporal dementia publication-title: Brain – volume: 21 start-page: 5 year: 2020 end-page: 14 article-title: Masitinib as an add‐on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 539 start-page: 197 year: 2016 end-page: 206 article-title: Decoding ALS: from genes to mechanism publication-title: Nature – volume: 3 start-page: 17085 year: 2017 article-title: Amyotrophic lateral sclerosis publication-title: Nat Rev Dis Primers – volume: 63 start-page: 724 year: 2004 end-page: 726 article-title: Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS publication-title: Neurology – volume: 15 start-page: 1182 year: 2016 end-page: 1194 article-title: Amyotrophic lateral sclerosis: moving towards a new classification system publication-title: Lancet Neurol – volume: 116 start-page: 2290 year: 2006 end-page: 2296 article-title: Antisense oligonucleotide therapy for neurodegenerative disease publication-title: J Clin Invest – volume: 124 start-page: 1708 year: 2001 end-page: 1719 article-title: Pathological laughter and crying: a link to the cerebellum publication-title: Brain – volume: 17 start-page: 1083 year: 2018 end-page: 1097 article-title: Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 publication-title: Lancet Neurol – volume: 319 start-page: 1668 year: 2008 end-page: 1672 article-title: TDP‐43 mutations in familial and sporadic amyotrophic lateral sclerosis publication-title: Science – volume: 87 start-page: 12 year: 2016 end-page: 20 article-title: Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients publication-title: J Neurol Neurosurg Psychiatry – volume: 466 start-page: 1069 year: 2010 end-page: 1075 article-title: Ataxin‐2 intermediate‐length polyglutamine expansions are associated with increased risk for ALS publication-title: Nature – volume: 314 start-page: 130 year: 2006 end-page: 133 article-title: Ubiquitinated TDP‐43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis publication-title: Science – volume: 13 start-page: 1127 year: 2014 end-page: 1138 article-title: Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? publication-title: Lancet Neurol – volume: 115 start-page: 495 year: 1992 end-page: 520 article-title: Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria publication-title: Brain – volume: 17 start-page: 423 year: 2018 end-page: 433 article-title: Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model publication-title: Lancet Neurol – volume: 19 start-page: 267 year: 2017 end-page: 274 article-title: Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians publication-title: Genet Med – volume: 90 start-page: 535 year: 2016 end-page: 550 article-title: Gain of toxicity from ALS/FTD‐linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC‐containing RNAs publication-title: Neuron – volume: 9 start-page: 995 year: 2010 end-page: 1007 article-title: TDP‐43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia publication-title: Lancet Neurol – volume: 19 start-page: 360 year: 2012 end-page: 375 article-title: EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force publication-title: Eur J Neurol – volume: 18 start-page: 153 year: 2017 end-page: 174 article-title: Amyotrophic lateral sclerosis – frontotemporal spectrum disorder (ALS‐FTSD): revised diagnostic criteria publication-title: Amyotroph Lateral Scler Frontotemporal Degener. – volume: 390 start-page: 2084 year: 2017 end-page: 2098 article-title: Amyotrophic lateral sclerosis publication-title: Lancet – year: 2016 – volume: 68 start-page: 1440 year: 2011 end-page: 1446 article-title: SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis publication-title: Arch Neurol – volume: 72 start-page: 245 year: 2011 end-page: 256 article-title: Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p‐linked FTD and ALS publication-title: Neuron – volume: 33 start-page: 630.e3 year: 2012 end-page: 630.e8 article-title: UNC13A is a modifier of survival in amyotrophic lateral sclerosis publication-title: Neurobiol Aging – volume: 81 start-page: 385 year: 2010 end-page: 390 article-title: Incidence of amyotrophic lateral sclerosis in Europe publication-title: J Neurol Neurosurg Psychiatry – volume: 70 start-page: 79 year: 2011 end-page: 83 article-title: Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study publication-title: Ann Neurol – volume: 16 start-page: 505 year: 2017 end-page: 512 article-title: Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double‐blind, placebo‐controlled trial publication-title: Lancet Neurol – volume: 89 start-page: 367 year: 2018 end-page: 373 article-title: Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis publication-title: J Neurol Neurosurg Psychiatry – volume: 76 start-page: 2066 year: 2011 end-page: 2072 article-title: Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2 publication-title: Neurology – volume: 18 start-page: 631 year: 2015 end-page: 636 article-title: Haploinsufficiency of TBK1 causes familial ALS and fronto‐temporal dementia publication-title: Nat Neurosci – volume: 477 start-page: 211 year: 2011 end-page: 215 article-title: Mutations in UBQLN2 cause dominant X‐linked juvenile and adult‐onset ALS and ALS/dementia publication-title: Nature – volume: 68 start-page: 857 year: 2010 end-page: 864 article-title: Exome sequencing reveals VCP mutations as a cause of familial ALS publication-title: Neuron – volume: 347 start-page: 1436 year: 2015 end-page: 1441 article-title: Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways publication-title: Science – volume: 72 start-page: 1087 year: 2009 end-page: 1094 article-title: Natural history and clinical features of the flail arm and flail leg ALS variants publication-title: Neurology – volume: 19 start-page: 118 year: 2018 end-page: 125 article-title: Trauma and amyotrophic lateral sclerosis: a European population‐based case–control study from the EURALS consortium publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 50 start-page: 894 year: 2014 end-page: 899 article-title: Patterns of clinical and electrodiagnostic abnormalities in early amyotrophic lateral sclerosis publication-title: Muscle Nerve – volume: 83 start-page: 1067 year: 2014 end-page: 1074 article-title: Functional pattern of brain FDG‐PET in amyotrophic lateral sclerosis publication-title: Neurology – volume: 265 start-page: 78 year: 2008 end-page: 83 article-title: Stem cell treatment in amyotrophic lateral sclerosis publication-title: J Neurol Sci – volume: 81 start-page: 1324 year: 2010 end-page: 1326 article-title: An estimate of amyotrophic lateral sclerosis heritability using twin data publication-title: J Neurol Neurosurg Psychiatry – volume: 36 start-page: 3116.e5 year: 2015 end-page: 3116.e8 article-title: TBK1 mutation frequencies in French frontotemporal dementia and amyotrophic lateral sclerosis cohorts publication-title: Neurobiol Aging – volume: 119 start-page: 497 year: 2008 end-page: 503 article-title: Electrodiagnostic criteria for diagnosis of ALS publication-title: Clin Neurophysiol – volume: 131 start-page: 1975 year: 2020 end-page: 1978 article-title: A proposal for new diagnostic criteria for ALS publication-title: Clin Neurophysiol – volume: 323 start-page: 1205 year: 2009 end-page: 1208 article-title: Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis publication-title: Science – volume: 97 start-page: 1268 year: 2018 end-page: 1283 article-title: Genome‐wide analyses identify KIF5A as a novel ALS gene publication-title: Neuron – volume: 267 start-page: 257 year: 2020 end-page: 258 article-title: Correction to: Longitudinal multi‐modal muscle‐based biomarker assessment in motor neuron disease publication-title: J Neurol – volume: 330 start-page: 585 year: 1994 end-page: 591 article-title: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group publication-title: N Engl J Med – volume: 76 start-page: 1367 year: 2019 article-title: Lifetime risk and heritability of amyotrophic lateral sclerosis publication-title: JAMA Neurol – volume: 141 start-page: 688 year: 2018 end-page: 697 article-title: Hot‐spot KIF5A mutations cause familial ALS publication-title: Brain – ident: e_1_2_13_6_1 doi: 10.1212/WNL.51.6.1546 – ident: e_1_2_13_33_1 doi: 10.1038/ng.442 – volume: 7 start-page: 181 year: 2015 ident: e_1_2_13_38_1 article-title: Risk factors for amyotrophic lateral sclerosis publication-title: Clin Epidemiol – ident: e_1_2_13_61_1 doi: 10.1093/brain/115.2.495 – ident: e_1_2_13_49_1 doi: 10.1186/s13024-019-0327-3 – ident: e_1_2_13_89_1 doi: 10.3727/096368912X633770 – ident: e_1_2_13_26_1 doi: 10.1126/science.1165942 – ident: e_1_2_13_62_1 doi: 10.3389/fneur.2019.00260 – ident: e_1_2_13_40_1 doi: 10.1038/nature20413 – ident: e_1_2_13_53_1 doi: 10.1212/WNL.0b013e3181b6bbbd – ident: e_1_2_13_8_1 doi: 10.1126/science.1134108 – ident: e_1_2_13_77_1 doi: 10.1038/gim.2016.107 – ident: e_1_2_13_31_1 doi: 10.1016/j.neurobiolaging.2015.08.009 – ident: e_1_2_13_48_1 doi: 10.1016/j.nbd.2017.02.004 – ident: e_1_2_13_2_1 doi: 10.1038/nrdp.2017.85 – ident: e_1_2_13_4_1 doi: 10.1016/S0140-6736(17)31287-4 – volume: 87 start-page: 12 year: 2016 ident: e_1_2_13_72_1 article-title: Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients publication-title: J Neurol Neurosurg Psychiatry – ident: e_1_2_13_64_1 doi: 10.3109/21678421.2015.1030430 – ident: e_1_2_13_13_1 doi: 10.1056/NEJM199403033300901 – ident: e_1_2_13_83_1 doi: 10.1080/21678421.2019.1632346 – ident: e_1_2_13_67_1 doi: 10.1016/S1474-4422(18)30089-9 – ident: e_1_2_13_22_1 doi: 10.1038/362059a0 – ident: e_1_2_13_74_1 doi: 10.1038/nrneurol.2011.153 – ident: e_1_2_13_84_1 doi: 10.1111/j.1468-1331.2011.03501.x – ident: e_1_2_13_36_1 doi: 10.1080/21678421.2017.1386687 – ident: e_1_2_13_15_1 doi: 10.1136/jnnp.2009.183525 – ident: e_1_2_13_45_1 doi: 10.15252/embj.201694401 – ident: e_1_2_13_32_1 doi: 10.1093/hmg/dds199 – ident: e_1_2_13_9_1 doi: 10.1080/146608200300079536 – ident: e_1_2_13_50_1 doi: 10.1212/01.WNL.0000134608.83927.B1 – ident: e_1_2_13_82_1 doi: 10.1080/21678421.2017.1369125 – ident: e_1_2_13_19_1 doi: 10.1001/jamaneurol.2019.2044 – ident: e_1_2_13_57_1 doi: 10.1007/s00415-019-09648-8 – ident: e_1_2_13_39_1 doi: 10.1016/S1474-4422(10)70195-2 – ident: e_1_2_13_47_1 doi: 10.1007/s00401-016-1586-5 – ident: e_1_2_13_76_1 doi: 10.1001/jamaneurol.2014.62 – ident: e_1_2_13_69_1 doi: 10.1016/j.nmd.2016.04.004 – ident: e_1_2_13_60_1 doi: 10.1136/jnnp.2010.235952 – ident: e_1_2_13_66_1 doi: 10.1016/j.neurobiolaging.2011.10.029 – ident: e_1_2_13_52_1 doi: 10.1016/j.neuron.2018.02.027 – ident: e_1_2_13_3_1 doi: 10.1056/NEJMra1603471 – ident: e_1_2_13_27_1 doi: 10.1016/j.neuron.2011.09.011 – ident: e_1_2_13_11_1 doi: 10.1002/ana.22380 – ident: e_1_2_13_25_1 doi: 10.1126/science.1166066 – ident: e_1_2_13_34_1 doi: 10.1038/nature09320 – ident: e_1_2_13_63_1 doi: 10.1212/01.wnl.0000345041.83406.a2 – ident: e_1_2_13_68_1 doi: 10.1001/archneur.57.1.109 – ident: e_1_2_13_73_1 doi: 10.1212/WNL.0000000000004029 – ident: e_1_2_13_79_1 doi: 10.1016/S0140-6736(96)91680-3 – ident: e_1_2_13_51_1 doi: 10.1093/brain/awx370 – ident: e_1_2_13_35_1 doi: 10.1212/WNL.0b013e31821f445b – ident: e_1_2_13_12_1 doi: 10.1016/j.clinph.2020.04.005 – ident: e_1_2_13_21_1 doi: 10.1136/jnnp.2010.207464 – ident: e_1_2_13_29_1 doi: 10.1126/science.aaa3650 – ident: e_1_2_13_16_1 doi: 10.1016/S1474-4422(18)30404-6 – ident: e_1_2_13_24_1 doi: 10.1038/ng.132 – ident: e_1_2_13_5_1 doi: 10.1016/S1474-4422(07)70265-X – ident: e_1_2_13_18_1 doi: 10.1007/s00415-006-0195-y – ident: e_1_2_13_81_1 doi: 10.1016/S1474-4422(17)30115-1 – ident: e_1_2_13_14_1 doi: 10.1016/S1474-4422(14)70129-2 – ident: e_1_2_13_88_1 doi: 10.1080/14653240802549470 – volume-title: Motor Neurone Disease: Assessment and Management year: 2016 ident: e_1_2_13_56_1 – volume: 46 start-page: 57 year: 2017 ident: e_1_2_13_17_1 article-title: Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta‐analysis publication-title: Int J Epidemiol – ident: e_1_2_13_20_1 doi: 10.3109/17482961003610853 – ident: e_1_2_13_58_1 doi: 10.1093/brain/124.9.1708 – volume: 7 start-page: 61 year: 2017 ident: e_1_2_13_80_1 article-title: Riluzole: real‐world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis publication-title: Degener Neurol Neuromuscul Dis – ident: e_1_2_13_41_1 doi: 10.1038/nature10353 – ident: e_1_2_13_54_1 doi: 10.1136/jnnp.2010.208413 – ident: e_1_2_13_10_1 doi: 10.1016/j.clinph.2007.09.143 – ident: e_1_2_13_42_1 doi: 10.1001/archneurol.2011.250 – ident: e_1_2_13_71_1 doi: 10.1136/jnnp-2017-316605 – ident: e_1_2_13_78_1 doi: 10.1212/WNL.0000000000003686 – ident: e_1_2_13_46_1 doi: 10.1111/j.1742-4658.2010.07643.x – ident: e_1_2_13_85_1 doi: 10.1172/JCI25424 – ident: e_1_2_13_23_1 doi: 10.1126/science.1154584 – ident: e_1_2_13_28_1 doi: 10.1016/j.neuron.2011.09.010 – ident: e_1_2_13_65_1 doi: 10.1080/21678421.2016.1267768 – ident: e_1_2_13_7_1 doi: 10.1093/brain/awr195 – ident: e_1_2_13_70_1 doi: 10.1136/jnnp.2009.186833 – ident: e_1_2_13_75_1 doi: 10.1212/WNL.0000000000000792 – ident: e_1_2_13_55_1 doi: 10.1002/mus.24244 – ident: e_1_2_13_59_1 doi: 10.1016/S1474-4422(16)30199-5 – ident: e_1_2_13_87_1 doi: 10.1016/j.jns.2007.05.016 – ident: e_1_2_13_43_1 doi: 10.1038/nature08971 – ident: e_1_2_13_86_1 doi: 10.1016/j.neuron.2016.04.006 – ident: e_1_2_13_37_1 doi: 10.1038/nrneurol.2013.203 – ident: e_1_2_13_30_1 doi: 10.1038/nn.4000 – ident: e_1_2_13_44_1 doi: 10.1016/j.neuron.2010.11.036
SSID	ssj0002720
Score	2.7200427
SecondaryResourceType	review_article
Snippet	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily the motor system, but in which extra‐motor manifestations are... Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily the motor system, but in which extra-motor manifestations are...
SourceID	pubmedcentral proquest pubmed crossref wiley
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1918
SubjectTerms	ALS and frontotemporal dementia Amyotrophic lateral sclerosis Autosomal dominant inheritance Brain stem Cortex (motor) Dementia Dementia disorders Differential diagnosis Epidemiology Frontotemporal dementia Genetics Health services Heredity Motor neurons Muscles Neurodegenerative diseases Pathogenesis Patients Review Spinal cord sporadic and familial ALS Symptom management TDP‐43 pathology
Title	Amyotrophic lateral sclerosis: a clinical review
URI	https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fene.14393 https://www.ncbi.nlm.nih.gov/pubmed/32526057 https://www.proquest.com/docview/2442707176 https://www.proquest.com/docview/2412989169 https://pubmed.ncbi.nlm.nih.gov/PMC7540334
Volume	27
WOSCitedRecordID	wos000545989200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1468-1331 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002720 issn: 1351-5101 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1468-1331 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002720 issn: 1351-5101 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9tAEB5Sp5Rc-k6iNAlK6aEXgXdX0krNySQ2LbQmhIb6JlbjFTY4crCcQP99Z1YPYtJAIBchoRFazey8tDvfAHyJkySyZPYCnKYmCMkHBLnIRSAKjbYIUYTGuGYTejxOJpP0YgtO21qYGh-i--HGmuHsNSu4yat7Sk6mgNRcpeoFbAuhEu7bIMOLzgzzAqPLtiIR8MRrYIV4G0_36KYzehBhPtwoeT-AdR5o9OZZY38Lr5vA0x_UM-UdbNnyPbz61Sytf4D-4Prvcr1a3szm6C8MFyYv_IpIaeTz6ptv_LaI0q_LXT7C1Wj4--x70LRTCJCiAhVYLFKLsp9MbZQba1KFhuI_iyRHiaZvKHmSiEpE07hgVBYba46pFMrQRtKqXeiVy9Lug28k6tQoMo19DBFFXhCzc3L-Ms71tEg8-NryNcMGa5xbXiyyNucgDmSOAx587khvaoCN_xEdtsLJGh2rMgpMpOZ0NPbgpLtN2sFLHqa0y1umEQwxL-LUg71alt1blIw4mdMe6A0pdwSMvL15p5zPHAK3pjhXqZA-00n58YFnw_HQnRw8nfQT7EhO6t2OwUPorVe39ghe4t16Xq2O3SSno54kx7B9fjm6-klXf36M_wFPngNT
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS-RADA9-ob7ofXlXv64e93AvhZ2ZttOKLyIrilruQdG3Ms1OcWGvK7vrwf33JtMPXPRA8K0wKZ0mk-SXmUkC8DNOksiS2QtwkJogJB8QFKIQgSg12jJEERrjmk3oLEvu7tLfC3DU5sLU9SG6DTfWDGevWcF5Q_qZlpMtID1XqVqE5ZCABjduuD3POjvMJ4wu3IpEwCuvqSvE93i6V-e90QuI-fKm5HME61zQ6eb7Jv8BNhro6R_Xa-UjLNjqE6xeNYfrn6F3_OffeDYZP9wP0R8ZTk0e-VMipakPp4e-8ds0Sr9OePkCN6f965OzoGmoECDhAhVYLFOLspcMbFQYa1KFhhCgRZKkRNMzFD5JRCWiQVxyXRYba0ZVCmVoI2nVFixV48p-A99I1KlRZBx7GCKKoiRuF-T-ZVzoQZl48KtlbI5NtXFuejHK26iDOJA7DnjwoyN9qEtsvEa020onb7RsmhM0kZoD0tiDg26Y9IMPPUxlx49MI7jIvIhTD77Wwuy-omTE4Zz2QM-JuSPg2tvzI9Xw3tXg1oR0lQrpN52Y_z_xvJ_13cP220m_w9rZ9dVlfnmeXezAuuQQ390f3IWl2eTR7sEK_p0Np5N9t-KfAA1QBBQ
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9RAEB_qtZS--FGtjZ6aig--BG53k2wivhz2DsX2KGKhb2Ez2dCDM3fcR6H_vTObD3qcguBbIBOymdmZ_U125zcAH-IkiSyFvQCL1AQhrQFBLnIRiFKjLUMUoTGu2YSeTJKbm_RqDz63tTA1P0T3w409w8VrdnC7KMoHXk6xgPxcpeoR7IfcRKYH--c_xtcXXSTmPUaXcEUi4LnXMAvxSZ7u4e31aAdk7p6VfIhh3SI0fvJ_w38Kjxvw6Q_r2fIM9mx1DIeXzfb6cxgMf93P18v54naK_sxwcfLMX5EoDX26-uQbvy2k9OuSlxdwPR79_PI1aFoqBEjIQAUWy9SiHCSFjXJjTarQEAa0SLaUaAaGEiiJqERUxCUzs9hYM65SKEMbSatOoFfNK3sKvpGoU6MoPA4wRBR5SdrOCQDIONdFmXjwsVVshg3fOLe9mGVt3kEayJwGPHjfiS5qko0_CfVb62SNn60yAidSc0oae3DW3SYP4W0PU9n5hmUE08yLOPXgZW3M7i1KRpzQaQ_0lpk7AWbf3r5TTW8dC7cmrKtUSJ_pzPz3gWejychdvPp30XdweHU-zi6-Tb6_hiPJOb47QNiH3nq5sW_gAO_W09XybTPlfwOyDwS9
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Amyotrophic+lateral+sclerosis%3A+a+clinical+review&rft.jtitle=European+journal+of+neurology&rft.au=Masrori%2C+P&rft.au=Van+Damme%2C+P&rft.date=2020-10-01&rft.eissn=1468-1331&rft.volume=27&rft.issue=10&rft.spage=1918&rft_id=info:doi/10.1111%2Fene.14393&rft_id=info%3Apmid%2F32526057&rft.externalDocID=32526057
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1351-5101&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1351-5101&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1351-5101&client=summon